Siliq market report points to faster growth in North America

The Business Research Company says the Siliq market is expanding on rising plaque psoriasis cases, broader biologics use and growing demand for personalized treatment. North America held the largest share in 2025 and is projected to grow fastest through the forecast period.

Why it matters: - The Siliq market is tied to a growing treatment need for adults with moderate to severe plaque psoriasis. - Demand is rising as dermatologists adopt more biologics and patients seek therapies that better target inflammation. - The market outlook matters for specialty drug developers, dermatology clinics and pharmacy networks serving chronic skin disease.

What happened: - The Business Research Company published its Siliq Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report says the Siliq market is gaining momentum as dermatology advances and awareness of skin conditions increases. - The company highlighted market size trends, growth drivers, regional dynamics and future market-shaping trends. - The report identifies North America as the largest market in 2025 and the fastest-growing region during the forecast period. - The regional scope includes Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also says its 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and key technology and future trend analysis.

The details: - Siliq is a prescription drug for adults with moderate to severe plaque psoriasis who need systemic therapy or phototherapy. - The drug works by inhibiting the IL-17A receptor, which is part of the inflammatory process linked to psoriasis. - The report says past market growth was driven by rising cases of moderate to severe plaque psoriasis, limited success of traditional systemic therapies, wider dermatologist acceptance of biologics, more specialty dermatology clinics and better diagnostic capabilities. - Future growth is expected to come from demand for next-generation biologics, stronger focus on long-term disease management, wider use of personalized immunology treatments, more investment in inflammation research and broader patient access to specialty therapies. - The report says key trends include broader use of targeted biologic therapies, more IL-17 pathway inhibitors, greater focus on individualized psoriasis treatment, expanding specialty pharmacy distribution networks and better treatment monitoring. - The report says rising skin disease prevalence is a major driver because skin conditions can stem from infections, autoimmune disorders, genetic predisposition, environmental factors and inflammation. - The report cites American Cancer Society data showing 108,270 skin cancer cases in the U.S. in January 2024, up 3.2% from the prior year. - The report says an aging population is also supporting demand because older adults often have fewer treatment options because of age-related health issues. - The report cites UK Parliament House of Commons Library data showing the UK had 12.7 million people age 65 or older in 2022, or 19% of the population, and that figure is expected to reach 22.1 million, or 27%, by 2072. - The report links precision medicine to Siliq market potential because tailored care based on genetics, environment and lifestyle is gaining traction. - The report cites the Personalized Medicine Coalition as saying the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022.

Between the lines: - The report’s framing suggests Siliq sits in a broader shift toward more targeted and individualized psoriasis care. - North America’s lead likely reflects stronger specialty-drug uptake, more advanced dermatology infrastructure and broader access to biologics. - The emphasis on specialty pharmacy channels and treatment monitoring points to a market that depends on long-term patient management, not one-time prescribing.

What's next: - The report expects continued growth from broader biologic adoption and more personalized treatment approaches. - Market attention will likely stay on IL-17 pathway therapies, specialty distribution and outcomes tracking. - The company says its report package includes a free sample and full report access for buyers tracking the category. - More information is available in the company’s announcement and the free sample report.

The bottom line: - Siliq’s market outlook is being lifted by rising psoriasis burden, precision-medicine adoption and stronger demand for targeted biologics, with North America leading the way.